<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528136</url>
  </required_header>
  <id_info>
    <org_study_id>CarbeteocinHeart2014</org_study_id>
    <nct_id>NCT02528136</nct_id>
  </id_info>
  <brief_title>The Clinical Carbetocin Myocardium Trial</brief_title>
  <acronym>CMT</acronym>
  <official_title>The Clinical Carbetocin Myocardium Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized comparison of different cardiotoxicity of carbetocin and oxytocin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carbetocin has been in clinical use in EU for some years and the efficacy is documented in&#xD;
      several RCTs. Circulatory adverse events leading to death has been reported after intravenous&#xD;
      injection of oxytocin. Some studies indicate that oxytocin may lead to dose dependent&#xD;
      ischemic ECG changes, prolongation of QT time and liberation of biomarkers of myocardial cell&#xD;
      death. Previously we have demonstrated comparable vasodilatory effects of oxytocin and&#xD;
      carbetocin. There is no clinical study comparing the specific myocardial effects of oxytocin&#xD;
      with carbetocin. It may have great impact on the choice of standard medication if the&#xD;
      cardiotoxicity of carbetocin is lower compared with oxytocin. The study of potential&#xD;
      cardiotoxicity has to be performed in healthy women. Knowing that millions of laboring women&#xD;
      have had uneventful injections of oxytocin and carbetocin after delivery, there is probably&#xD;
      no reason to fear long lasting negative effects of either drug. If there are differences in&#xD;
      cardiotoxicity, this new information should be taken into consideration when planning&#xD;
      delivery in pregnant women with heart disease.&#xD;
&#xD;
      The aims of this study are to compare 0h (before C-section), 4h, 12h, 24h, and 48h plasma&#xD;
      concentrations of Troponin I, Troponin T, proBNP, CK, and other relevant myocardial markers&#xD;
      in elective healthy C-section patients randomized to oxytocin 2.5 U or carbetocin 100 µg, 1&#xD;
      minute injection immediately after delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 28, 2019</completion_date>
  <primary_completion_date type="Actual">January 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P-Troponin I</measure>
    <time_frame>48 hours</time_frame>
    <description>P-Troponin I group differences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>P-Biomarkers</measure>
    <time_frame>48 hours</time_frame>
    <description>P-Biomarkers group differences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG-changes</measure>
    <time_frame>1 hour</time_frame>
    <description>Group differences in ECG-changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>48 hours</time_frame>
    <description>Calculated estimated blood loss (group differences in Hb change)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain intensity</measure>
    <time_frame>48 hours</time_frame>
    <description>Group differences in pain intensity (Numeric rating scale 0 - 10) and consumption of PCA Morphine</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One minute injection of carbetocin 100 µg after the delivery of the baby</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One minute injection of oxytocin 2.5 U after the delivery of the baby</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Pabal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy pregnant women age 18 to 50&#xD;
&#xD;
          2. Singleton pregnancy at gestational age 36 weeks or more&#xD;
&#xD;
          3. Able to read and understand Norwegian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with placenta pathology such as praevia, acreta, pre-eclampsia&#xD;
&#xD;
          2. Patients with bleeding disorders including vonWillebrand disease type I.&#xD;
&#xD;
          3. Known intolerance to one of the two drugs.&#xD;
&#xD;
          4. Patients with prolonged QT-time or other serious cardiac diseases.&#xD;
&#xD;
          5. Liver or kidney failure.&#xD;
&#xD;
          6. Epilepsy.&#xD;
&#xD;
          7. Any medical reason why, in the opinion of the investigator, the patient should not&#xD;
             participate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leiv Arne Rosseland, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dep of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital, Division of Emergencies and Critical Care</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Leiv Arne Rosseland</investigator_full_name>
    <investigator_title>Head for R&amp;D department</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participant data will be analyzed in the Research Group only</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02528136/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

